First-in-class
drugs through
targeted stabilization
of protein complexes
First-in-class drugs through
targeted stabilization
of protein complexes
APPROACH
Driven by the need for new therapeutic options for cancer patients, our team is harnessing our deep scientific expertise and drug discovery know-how to create first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments.
Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. Ambagon’s platform approach will also open opportunities to address other major unmet clinical needs.
Ambagon has sites in San Francisco, CA, USA and Eindhoven, Netherlands
TEAM
Ambagon was inspired by the world-class research in the laboratories of our co-founders.
COFOUNDERS:
LEADERSHIP:
NEWS
Ambagon’s novel approach was recognized with several awards during early company formation.
Ambagon was awarded two Golden Tickets, which provide one year’s priority admission or renewal to MBC BioLabs’ state-of-the-art laboratory. Ambagon was awarded a Golden Ticket each from AbbVie Ventures and Astellas Venture Management in 2019. Read the announcement of the Astellas Golden Ticket here:
https://mbcbiolabs.com/mbc-biolabs-news/announcing-winners-of-the-2019-astellas-golden-ticket/
Ambagon was also the winner of the Dutch Venture Challenge and was awarded a prize of €25,000. Read about Ambagon winning the Dutch Venture Challenge here:
https://www.health-holland.com/news/2019/06/the-winner-of-the-venture-challenge-is-ambagonand
CONTACT
SAN FRANCISCO
953 Indiana Street
San Francisco, CA 94107
EINDHOVEN
Catalyst 1.21, De Lismortel
31 5612 AR, Eindhoven, NL